Company Overview of Oncimmune Holdings Plc
Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer in the United Kingdom and North America. The company engages in the development of autoantibody assay technologies to allow cancer detection to a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company also develops EarlyCDT tests for liver and ovarian cancer. Oncimmune Holdings Plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
Clinical Sciences Building
Nottingham City Hospital
Nottingham, NG5 1PB
Founded in 2015
44 1158 231 869
44 1158 231 958
Key Executives for Oncimmune Holdings Plc
Oncimmune Holdings Plc Key Developments
Similar Private Companies By Industry
|Achilles Therapeutics Ltd.||Europe|
Recent Private Companies Transactions
February 5, 2018
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Oncimmune Holdings Plc, please visit www.oncimmune.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.